Fresenius SE KGaAXSWX:FRE 71 EV-to-EBIT is 12.13 as of Jul. 01, 2026, which is 11% below its 10-year median of 13.62. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF33.07 (Fairly Valued). The stock has 5 warning signs investors should review. Among 471 Healthcare Providers & Services companies, Fresenius SE KGaA ranks better than 63.91% on this metric.
The historical rank and industry rank for Fresenius SE KGaA's EV-to-EBIT or its related term are showing as below:
XSWX:FRE'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8.9 Med: 13.62 Max: 34.03
Current: 12.23
During the past 13 years, the highest EV-to-EBIT of Fresenius SE KGaA was 34.03. The lowest was 8.90. And the median was 13.62.
XSWX:FRE's EV-to-EBIT is ranked better than 63.91% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.69
vs XSWX:FRE: 12.23
Fresenius SE KGaA (XSWX:FRE) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fresenius SE KGaA's Enterprise Value for the quarter that ended in Mar. 2026 was CHF30,735 Mil.
Fresenius SE KGaA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,366 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA EV-to-EBIT Related Terms
Fresenius SE KGaA EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Fresenius SE KGaA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's EV-to-EBIT falls into.
Fresenius SE KGaA's current Enterprise Value is CHF28,707 Mil.
Fresenius SE KGaA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,366 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (XSWX:FRE) has a EV-to-EBIT of 12.13 as of Jul. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fresenius SE KGaA and its competitors. This is 11% below median its historical median of 13.62. Over the past decade, Fresenius SE KGaA's EV-to-EBIT has ranged from 8.90 to 34.03. According to the industry distribution chart, Fresenius SE KGaA ranks #170 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 36.1%.
Is Fresenius SE KGaA's EV-to-EBIT too high?
Fresenius SE KGaA's current EV-to-EBIT of 12.13 is 11% below median its 10-year median of 13.62. Over the past 10 years, this metric has ranged from a low of 8.90 to a high of 34.03. The Healthcare Providers & Services industry median EV-to-EBIT is 15.69. Fresenius SE KGaA's value of 12.13 is 22.7% below this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #170 out of 471 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #170 out of 471 companies for EV-to-EBIT. This puts Fresenius SE KGaA in the upper half of its industry. The industry median EV-to-EBIT is 15.69. Fresenius SE KGaA's value of 12.13 is 22.7% below this benchmark. Historically, Fresenius SE KGaA's own EV-to-EBIT has ranged from 8.90 to 34.03 over the past decade. While the company's 10-year median is 13.62 vs. the industry median of 15.69, Fresenius SE KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.69, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current EV-to-EBIT of 12.13 is 22.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current EV-to-EBIT is 12.13, which is 11% below median its own 10-year median of 13.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF33.07, compared to a current price of CHF36.15 — trading 9.3% above its estimated fair value. The current EV-to-EBIT is 12.13, which is 11% below median its 10-year median of 13.62 and 22.7% below the Healthcare Providers & Services industry median of 15.69. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current EV-to-EBIT is 12.13 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF36.15 is trading 9.3% above its estimated GF Value™ of CHF33.07.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for XSWX:FRE:
EV-to-EBIT: 12.13 (11% below median its 10-year median of 13.62)
GF Value™: CHF33.07 vs. price of CHF36.15 (9.3% above fair value)
Industry Position: 22.7% below the Healthcare Providers & Services median (#170 of 471)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score
Get the complete analysis for XSWX:FRE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
